EIGR - Eiger BioPharmaceuticals, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
8.70
+0.05 (+0.58%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.65
Open8.75
Bid0.00 x 0
Ask0.00 x 0
Day's Range8.60 - 8.75
52 Week Range6.10 - 16.20
Volume49,263
Avg. Volume154,445
Market Cap91.493M
Beta1.55
PE Ratio (TTM)N/A
EPS (TTM)-5.30
Earnings DateMar 21, 2018 - Mar 26, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.33
Trade prices are not sourced from all markets
  • PR Newswire16 days ago

    Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February

    PALO ALTO, Calif. , Feb. 6, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today ...

  • 3 Pharma and Biotech Stocks to Watch Out for in 2018
    InvestorPlacelast month

    3 Pharma and Biotech Stocks to Watch Out for in 2018

    2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE ARCA Pharmaceutical index gaining 18.7% and 11.8%, respectively. There was a significant surge in FDA approvals, investors appeared more comfortable with the drug pricing controversy and innovation won the day with the FDA granting approval to gene therapies for cancer as well as a rare form of blindness. As we start the New Year, here is a look at three drug stocks that look well-positioned for 2018 and are witnessing upward estimate revisions and have a favorable Zacks Rank – Zacks Rank #1 (Strong Buy) or #2 (Buy).

  • Market Exclusivelast month

    These Two Biotechs Just Reported Key Data

    Both Merck (NYSE:MRK) and Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) put out clinical trial data this week and the two companies have moved considerably on the back of the update. Here is a look at the data we got from each and what it means for both the companies in question and the target populations to which […] The post These Two Biotechs Just Reported Key Data appeared first on Market Exclusive.

  • 24/7 Wall St.last month

    Why Eiger BioPharma Shares Are Getting Crushed

    Eiger BioPharmaceuticals watched its shares crater on Tuesday after the firm announced that its midstage study in pulmonary arterial hypertension did not meet its primary endpoint.

  • MarketWatchlast month

    Eiger shares plummet 40% after phase 2 trial failure

    Eiger BioPharmaceuticals Inc. shares dropped more than 40% in premarket trade Tuesday after the company said its pulmonary arterial hypertension drug failed to meet a primary and secondary endpoint both ...

  • PR Newswirelast month

    Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint

    - End of Phase 2 Meeting Scheduled for HDV in February 2018 - Phase 2 Readouts for PBH and Lymphedema in Second Half 2018 PALO ALTO, Calif. , Jan. 16, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. ...

  • PR Newswirelast month

    Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors

    PALO ALTO, Calif., Jan. 8, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Eldon Mayer to its Board of Directors.  Mr. Mayer is a pharmaceutical industry veteran with broad commercial experience which spans over two decades in large pharma and specialty pharma across oncology, inflammatory disease, pulmonary disease, dermatology and rare diseases, with multiple successful exits by acquisition. "I am very pleased to join Eiger's Board at this exciting point in the Company's evolution to late stage development, and look forward to working closely with the other Board members and Eiger's management team to advance a diverse set of exciting clinical stage orphan disease programs in therapeutic areas of high unmet medical need," said Mr. Mayer.

  • PR Newswire2 months ago

    Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients

    - ULTRA Study Data Expected in Second Half 2018 PALO ALTO, Calif. , Jan. 4, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted ...

  • PR Newswire2 months ago

    Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer

    PALO ALTO, Calif., Jan. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, PhD, MBA as Chief Operating Officer and Executive Medical Officer.  Dr. Apelian's clinical development and regulatory experience spans 17 years between large pharma and biotechnology companies in all phases of development ranging from discovery to registration, across multiple therapeutic areas including gastroenterology, hepatology, immuno-oncology, infectious diseases, and rare diseases. "I am very pleased to join Eiger's executive team at this exciting point in the Company's development, and look forward to working closely with Eiger management to advance a diverse set of exciting clinical stage orphan disease programs in therapeutic areas of high unmet medical need," said Dr. Apelian.

  • PR Newswire2 months ago

    Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018

    PALO ALTO, Calif. , Jan. 2, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today ...

  • Why Eiger BioPharmaceuticals (EIGR) Could Be Positioned for a Surge
    Zacks2 months ago

    Why Eiger BioPharmaceuticals (EIGR) Could Be Positioned for a Surge

    Eiger BioPharmaceuticals (EIGR) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

  • PR Newswire3 months ago

    Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference

    PALO ALTO, Calif., Nov. 13, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate update at Jefferies 2017 Healthcare Conference on Thursday, November 16, 2017 at 4:40 pm CET at the Waldorf Hilton London in the Westminster Room on the Entresol Level.  Eiger will also host one-on-one meetings. Eiger is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for orphan diseases.  We are committed to translational innovation and the repurposing of well-characterized drugs acting on newly identified or novel targets.  Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients with orphan diseases.  For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

  • Associated Press3 months ago

    Eiger BioPharma reports 3Q loss

    The Palo Alto, California-based company said it had a loss of $1.10 per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • PR Newswire3 months ago

    Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results

    -Clinical Results Planned in Each of Four Orphan Disease Programs by 4Q 2018 -Cash Runway Extends Through Mid-2019 PALO ALTO, Calif. , Nov. 9, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: ...

  • Should Your Next Investment In The Healthcare Industry Be In Eiger BioPharmaceuticals Inc (EIGR)?
    Simply Wall St.3 months ago

    Should Your Next Investment In The Healthcare Industry Be In Eiger BioPharmaceuticals Inc (EIGR)?

    Eiger BioPharmaceuticals Inc (NASDAQ:EIGR), a USD$118.65M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, andRead More...

  • Does Eiger BioPharmaceuticals Inc’s (EIGR) Debt Level Pose A Serious Problem?
    Simply Wall St.4 months ago

    Does Eiger BioPharmaceuticals Inc’s (EIGR) Debt Level Pose A Serious Problem?

    While small-cap stocks, such as Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) with its market cap of USD $119.70M, are popular for their explosive growth, investors should also be aware of their balanceRead More...

  • PR Newswire4 months ago

    Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock

    PALO ALTO, Calif., Oct. 27, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of 1,854,749 shares of its common stock at a price of $10.00 per share, before underwriting discounts and commissions.  All of the shares of common stock to be sold in the offering are to be sold by Eiger.  In addition, Eiger has granted to the underwriter a 30-day option to purchase up to 278,212 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

  • PR Newswire4 months ago

    Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock

    PALO ALTO, Calif., Oct. 26, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  Eiger intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.  All of the shares of common stock to be sold in the offering will be offered by Eiger.  There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. BTIG, LLC is acting as sole book-running manager for the offering.

  • PR Newswire4 months ago

    Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting

    PALO ALTO, Calif. , Oct. 23, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced positive interim 24-week data with pegylated interferon lambda (Lambda) in the Phase 2 LIMT ...

  • PR Newswire5 months ago

    Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting

    PALO ALTO, Calif. , Oct. 2, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that two abstracts will be presented at the American Association for the Study of Liver Diseases ...

  • PR Newswire5 months ago

    Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors

    PALO ALTO, Calif., Sept. 18, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Evan Loh, MD to its Board of Directors.  Dr. Loh's clinical development and regulatory experience spans nearly two decades across all phases of development ranging from discovery to registration, across multiple therapeutic areas including oncology, infectious diseases, inflammation and rare diseases.  The company concurrently announced that Ed Engleman, MD, Managing Partner at Vivo Capital and a founding venture investor, is departing from the Board.

  • PR Newswire6 months ago

    Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

    PALO ALTO, Calif., Sept. 5, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan designation for pegylated interferon lambda 1a (Lambda) as a potential treatment for chronic hepatitis delta virus (HDV) infection.

  • PR Newswire6 months ago

    Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences

    PALO ALTO, Calif. , Aug. 30, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today ...

  • Associated Press6 months ago

    Eiger BioPharma reports 2Q loss

    On a per-share basis, the Palo Alto, California-based company said it had a loss of $1.33. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • PR Newswire6 months ago

    Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results

    - Five Phase 2 Programs Advancing in Multiple Orphan Indications - Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif. , Aug. 14, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, ...